The New Frontiers of Mental Health — Brain Stimulation, Rapid-Acting Tools for Depression, and More

Deardra Lehman's husband, who was instrumental in philanthropic efforts to fund trials and advocate for accelerated TMS after his wife's dramatic recovery.

The first antipsychotic drug, discovered serendipitously and used to deinstitutionalize schizophrenia patients, marking a shift in psychiatric treatment from content to chemical approaches.

A nonprofit organization that partnered with Dr. Williams to study ibogaine as a treatment for veterans with traumatic brain injury.

Interviewed by the host at a Veterans Day fundraiser, where psychedelic treatments were likely among the topics discussed.

A renowned chemist known for synthesizing and studying psychoactive compounds, mentioned for his ability to emulate 5-HT2A effects, but contrasting with the complexity of ibogaine's multi-receptor 'symphony'.

Administered intravenously as a treatment for torsades de pointes, the arrhythmia associated with ibogaine, to mitigate cardiac risk.

Reported to have sold less food, illustrating the societal impact of drugs like Ozempic on consumer habits.

Another tree in Ghana and other parts of Africa that contains Voacangine, an alkaloid similar to ibogaine, which is not a controlled substance and can be chemically converted to ibogaine.

Technology being used in a study to open nanoparticle-packaged ketamine and selectively deliver it to specific brain regions like the cingulate, potentially for pain patients.

A country in South America mentioned as a destination Dr. Williams was traveling to when he read about ibogaine.

A movie starring Tom Cruise, used as an analogy to describe the ibogaine 'slideshow' experience where individuals observe their past experiences from a neutral, third-party perspective.

A diabetes drug that has shown significant weight loss and a reduction in various cravings, leading to unexpected societal ripple effects like decreased snack food sales. Compared to ibogaine for its habit-affecting properties.

A substance with potential for broad population-based use in PTSD treatment, distinct from ibogaine and 5-MeO-DMT due to its different risk profile and therapeutic mechanism.

Developed TMS in the UK in the mid-80s as a motor probe to map brain function non-invasively.

A psychiatric treatment, around for 100 years, that aims to produce a therapeutic seizure, distinct from TMS, and often underutilized due to stigma and side effects like memory troubles.

A commonly known SSRI antidepressant mentioned as an example of a low side-effect burden oral antidepressant in the Star*D study algorithm.

An antiarrhythmic drug approved for atrial fibrillation, mentioned for having pro-arrhythmic risks similar to ibogaine, but safely administered in monitored cardiac settings.

A journalist who wrote a piece for National Geographic on ibogaine/iboga and a book on MDMA-assisted psychotherapy, traveling to Gabon to investigate.

Suggested as a sustainable alternative to peyote due to different growth cycles, in a broader discussion on ethical psychedelic sourcing.

A prestigious medical journal where a paper on ketamine's efficacy was published.

A country in Central West Africa where the iboga root bark, the source of ibogaine, has been utilized for millennia.

A psychedelic drug mentioned to illustrate diverse receptor system effects, primarily a Kappa agonist, contrasting with ibogaine's broad range of action.

A diet low in carbohydrates and high in fat, suggested as a potential 'accelerated TMS equivalent' for certain psychiatric conditions, demonstrating remarkable transformations in some patients.

Mentioned as a common activity patients engage in during TMS sessions, highlighting the low impact and non-sedative nature of the treatment.

A drug that produces about a 30% spot remission rate with a single infusion for depression, with efficacy increasing with more treatments, though it accumulates more time compared to Saint.

A colleague at Cornell who, with his team, replicated the finding of a subpopulation of patients experiencing slower remission times with TMS.

An atypical psychedelic, or 'neurogen,' derived from the iboga root bark, being investigated as a potential treatment for military traumatic brain injury, depression, anxiety, PTSD, and various addiction types, offering rapid and durable effects.

A top biomedical journal that published Dr. Williams' open-label paper on ibogaine as a treatment for military traumatic brain injury, depression, generalized anxiety disorder, and PTSD.

A short-acting psychedelic found in plants and the Colorado River toad (Bufo alvarius), discussed for its use on the 'gray day' following ibogaine administration and its potential risks and sustainability concerns.

A famous musician whose music a patient with OCD became obsessed with after deep brain stimulation, illustrating unintended and surprising effects of brain interventions on personal taste and content.

A peer-reviewed scientific journal where a paper on brain activation sequencing and its relevance to mood disorders was published.

A non-invasive brain stimulation technique, developed in the mid-80s, that uses a pulsed electromagnet to induce current in brain tissue, used initially as a motor probe and later adapted for therapeutic purposes.

The principle that if a magnet is pulsed, it can generate current in electrically conducting substances, forming the basis for how TMS works.

Approved TMS in the mid to late 2000s and later cleared accelerated TMS protocols (SAINT) in 2018 for major depressive disorder.

Interviewed by the host at a Veterans Day fundraiser, where psychedelic treatments were likely among the topics discussed.

Author of 'Breaking Up in the Head', who wrote about his personal experience with ibogaine, influencing Dr. Williams' early interest.

Mentioned as an example of a 'promiscuous' drug that interacts with multiple receptor systems, similar to ibogaine's complex action.

Pioneering figure who tried to advance ibogaine through FDA and NIH in the 1990s, recognizing its potential as an anti-addiction drug.

Published case report level outcomes on ibogaine, including its cardiac problems, contributing to the early understanding of the drug.

Actor in 'The Minority Report', referenced by Dr. Williams to illustrate the life review experience under ibogaine.

An African country where Voacanga trees grow, which contain a similar alkaloid to ibogaine.

Newly branded psychedelics with the 'content' or mind-altering aspects removed as much as possible, focusing on neuroplasticity without the full psychedelic experience.

Host of the Huberman Lab podcast, from whose conversation with Dr. Williams a snippet on brain activation sequencing was pulled for discussion.

An imaging technique used to observe brain regions with time-locked blood flow (resting state functional connectivity MRI), providing a surrogate measure of electrical activity in the brain.

Mentioned as an example of a drug discovered serendipitously for an unrelated condition (angina) but found to have a different primary use (erectile dysfunction).

A rapid-acting neurostimulation approach developed from reorganizing conventional TMS, personalizing it to each person's brain, and compressing six-week treatment courses into a single day.

Dr. Williams' mentor, who first used TMS as a therapeutic tool in clinical trials at NIH in the mid-90s, leading to its eventual FDA approval.

The entity that reviews all research protocols at institutions to ensure they are ethical, safe, and answer proposed questions. Dr. Williams sought and received IRB approval for accelerated TMS and later for the ibogaine study.

A colleague at Harvard who conducted studies showing that TMS stimulation can release endogenous opioids, leading to anti-pain effects that can be blocked by opioid blockers.

A psychedelic drug typically affecting 5-HT2A receptors, producing classic psychedelic experiences. Mentioned in context of comparisons with ibogaine and its use in trials for alcohol use disorder.

Involved in advocacy for ibogaine research and treatment for veterans, as part of the VETS organization.

An organization that funded earlier research on ibogaine and potentially other psychedelic drugs, though with caution due to the complexities and risks.

A publication Daniel Pinchbeck wrote for.

An airport where Dr. Williams picked up a book about ibogaine while waiting for a delayed flight.

Legislation that has recently passed the Senate and House, moving to President Biden to earmark money for ibogaine trials, indicating growing government interest in psychedelic research for veterans.

An institution where groups are actively researching ways to modify the ibogaine molecule to reduce its cardiac risk profile.

An institution where groups are actively researching ways to modify the ibogaine molecule to reduce its cardiac risk profile, coining terms like 'iboga logs'.

Their guidelines recommend IV Magnesium as a treatment for torsades de pointes, a cardiac arrhythmia of concern with ibogaine.

A Harvard researcher and advocate for metabolic psychiatry, researching the use of ketogenic diets for psychiatric conditions like schizophrenia.

A publication that featured a piece by journalist Rachel Nuwer on the global demand and ethical implications of ibogaine/iboga harvesting.

An African country where iboga can also be found, in addition to Gabon.

A natural psychedelic cactus, mentioned in the context of diminishing natural supplies and the ethical imperative to consider sustainable alternatives.

An organization whose members use peyote as an integral part of their tradition and healing, highlighting the importance of cultural context in psychedelic use.

A writer and filmmaker known for advocating for the synthesis of 5-MeO-DMT to address environmental and ethical concerns associated with toad harvesting.

A surgical form of neuromodulation involving an implanted device in the brain, used for conditions like OCD and addiction, but carries risks like head bleeds. Mentioned as a potential future intervention for content manipulation.